Antibody Information
General Information of This Antibody (ID: ANTI0UFAFI)
| Antibody Name | Anti-c-MET pH-dependent mAb |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | c-Met |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
MYTX-011 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion: NSCLC patients (Part 1: advanced/metastatic; Part 2: stratified by cMET expression/EGFR status) with ≥1 measurable lesion, ECOG 0-1, prior SOC therapy. Exclusion: Recent radiation/surgery (6w/28d), active CNS metastases, interstitial lung disease, Grade>1 neuropathy, hepatic/corneal disorders, or uncontrolled infections. Contraception required for 6 months post-treatment.
Click to Show/Hide
|
||||
| Administration Dosage |
MYTX-011 will be administered as an intravenous infusion every 21 days.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05652868 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
|
||||
| Primary Endpoint |
Primary endpoints include DLT assessment (treatment-related AEs) in Part 1 (21-day evaluation) and tumor response rate (CR+PR) in Part 2 (2-year follow-up).
|
||||
| Other Endpoint |
Secondary objectives comprise PK analysis (total ADC/antibody/free MMAE), ADA detection, ORR/DOR/TTR/DCR assessment, and survival outcomes (PFS/OS) with 24-month monitoring in Part 1.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05652868 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.
|
||||
References